GlassScriptPhysician profile
Simran-Jyot A Elder
NPI 1073856738
$576.65
in general payments reported to CMS, 2019-2025
14 companies · $95.33 in 2025
The $95.33 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.10 · 2022: $217 · 2023: $123 · 2024: $60.47 · 2025: $95.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $253 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $253.36 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $108.41 | 2021-2025 | Trodelvy |
| Pfizer INC. | $96.05 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $70.63 | 2022 | |
| Abbvie INC. | $64.32 | 2024-2025 | |
| Daiichi Sankyo INC. | $39.01 | 2021-2025 | Enhertu |
| Celgene Corporation | $33.94 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $32.68 | 2022-2023 | Opdualag |
| Amgen INC. | $30.69 | 2022 | |
| Merck Sharp & Dohme LLC | $20.20 | 2023 | Keytruda |
| Novocure INC. | $18.64 | 2021 | |
| Karyopharm Therapeutics INC. | $16.50 | 2022 | |
| Eisai INC. | $16.00 | 2023 | |
| Blueprint Medicines Corporation | $15.22 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simran-Jyot Elder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.